Page 35

Junio 2017

ARTÍCULO DE INVESTIGACIÓN 715 vatives: A Systematic Review. Adv Pharmacol Sci 2015; 507151. 14. Shah R, Rogers KC, Matin K, Askari R, Rao SV. An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention. Am Heart J 2016; 171 (1): 14-24. 15. Pieri M, Agracheva N, Bonaveglio E, Greco T, De Bonis M, Covello RD, et al. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. J Cardiothorac Vasc Anesth 2013; 27 (1): 30-4. 16. Sanfilippo F, Asmussen S, Maybauer DM, Santonocito C, Fraser JF, Erdoes G, et al. Bivalirudin for Alternative Anticoagulation in Extracorporeal Membrane Oxygenation: A Systematic Review. J Intensive Care Med 2016; 29: Epub ahead of print. 17. Jyoti A, Maheshwari A, Daniel E, Motihar A, Bhathiwal RS, Sharma D. Bivalirudin in venovenous extracorporeal membrane oxygenation. J Extra Corpor Technol 2014; 46 (1): 94-7. 18. Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P, et al. Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Investigators. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J 2014; 35 (34): 2285-94. 19. Steg PG, van ‘t Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, et al. EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369 (23): 2207-17. 20. Burcham PK, Rozycki A, Abel E. Considerations for analgosedation and antithrombotic management during extracorporeal life support. Ann Transl Med 2017; 5 (4): 69. Bivalirudina en ECMO - N. Van Sint Jan et al Rev Med Chile 2017; 145: 710-715


Junio 2017
To see the actual publication please follow the link above